医師の世論調査：医師がMSLに本当に求めているもの、改善すべき点

背景

MSLの役割が治療領域戦略の形成において戦略的で影響力のあるものとして認識されるようになるにつれ、製薬企業にとって、医療従事者（HCP）がMSLとの交流に何をもっとも望んでいるかを理解し、MSLが彼らのニーズにどの程度効果的に応えているかを測定することが不可欠となっています。例えば、COVID-19パンデミック以来増加したハイブリッドエンゲージメントモデルに関して、MSLとHCPは同じ考えを持っているでしょうか。

当レポートでは、フランス、ドイツ、イタリア、スペイン、英国、米国の医師417人を対象に世論調査を行い、彼らがMSLとのやりとりについてどのように感じているか、またそれらはどのように改善できるかをまとめています。医師たちは、循環器科、内分泌科、神経科、腫瘍科、リウマチ科の5つの専門分野で活動しています。

回答された主な質問

• 1. 製薬企業のメディカルサイエンスリエゾン（MSL）担当者との現在のやりとりについて、全体としてどの程度満足しているか（注：営業担当者ではない）
• 2. 製薬企業のMSLとどのようにコミュニケーションを取りたいか（注：営業担当者ではない）
• 3. 通常、MSLが提供する未承諾の科学的情報や製品情報は、自身や自身が行う診療にとってどの程度有用か
• 4. 製薬企業のMSLとどのくらいの頻度で交流したいか（注：営業担当者ではない）
• 5. 製薬企業のMSLとの交流経験をもっとも向上させるために、どのような点を変更したいか（注：営業担当者ではない）

The backstory:

As the MSL role is increasingly recognised as more strategic and influential in shaping therapeutic area strategies, it is vital for pharmaceutical companies to understand what healthcare professionals (HCPs) want most from MSL interactions and to gauge how effectively MSLS are meeting their needs. For instance, are MSLs and HCPs on the same page when it comes to the hybrid engagement models that have increased since the COVID-19 pandemic?

The physician view:

FirstWord recently polled 417 doctors from France, Germany, Italy, Spain, the UK and US to gain an inside look at how they feel about their MSL interactions and how they could be improved. These physicians work across five specialties: cardiology, endocrinology, neurology, oncology and rheumatology.

Key Questions Answered:

• 1. How satisfied are you overall with your current interactions with medical science liaison (MSL) representatives from pharmaceutical companies? (note: not sales representatives)
• 2. How would you prefer to communicate with MSLs from pharmaceutical companies? (note: not sales representatives)
• 3. Typically, how useful is the unsolicited scientific and product information MSLs provide to you and your practice?
• 4. Please indicate how often you would like to interact with MSLs from pharmaceutical companies? (note: not sales representatives).
• 5. What one change would most improve your interaction experience with MSLs from pharmaceutical companies? (note: not sales representatives)

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.